Sorafenib for Treatment of Hepatocellular Carcinoma: A Systematic Review

Xie, Bingru; Wang, David H.; Spechler, Stuart J.

doi:10.1007/s10620-012-2136-1

Cited by 107 publications

(89 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These facts can also explain the most significant radiological TTP in this study compared with the SHARP study [12 vs. 5.5 months]. The AEs were moderate [grade 1 or 2] and symptom treatment and dose adjustments were usually enough tomanage AEs [40,44]. Xie et al demonstrated that sorafenib treatment is significant from the statistical point of view, but clinically only modest improvements in OS, TTP and DCR have been demonstrated [45].…”

Section: Molecular Targeted Therapymentioning

confidence: 55%

See 1 more Smart Citation

Management of Hepatocellular Carcinoma: An Update at the Start of 2014

Ardiri¹

2014

J Gastroint Dig Syst

View full text Add to dashboard Cite

show abstract

Section: Molecular Targeted Therapymentioning

confidence: 55%

“…In clinical practice, the failure of locoregional therapy, such as TACE, led to the use of sorafenib. Its efficacy and safety in HCC patients was demonstrated by the SHARP trial in western patients [40].…”

Section: Molecular Targeted Therapymentioning

confidence: 99%

Management of Hepatocellular Carcinoma: An Update at the Start of 2014

Ardiri¹

2014

J Gastroint Dig Syst

View full text Add to dashboard Cite

show abstract

“…[12] Therefore, we expect that sorafenib will help block the progress of hepatitis B and prevent the development of HCC. This might be a unique advantage as an antiviral drug because other currently available anti-HBV agents don't have oncomodulatory effects.…”

Section: Discussionmentioning

confidence: 99%

Sorafenib suppresses hepatitis B virus gene expression via inhibiting JNK pathway

et al. 2015

View full text Add to dashboard Cite

Aim: Hepatitis B virus (HBV) infection is a major cause of chronic liver diseases. Sorafenib is a multikinase inhibitor and an approved anti-liver cancer drug. Here we demonstrated the antiviral effect of sorafenib on HBV gene expression. Methods: To investigate the effect of sorafenib on HBV gene expression, a luciferase assay was performed with ×1.3 Cp-luciferase HBV construct and reverse transcriptase polymerase chain reaction (PCR), real-time PCR, and Western blotting analyses were performed using HepG2 cells derived from hepatocellular carcinoma and Chang liver cells derived from a normal liver tissue. Results: Sorafenib suppressed HBV gene expression via inhibiting the JNK pathway. In this process, the farnesoid X receptor (FXR), a transcription factor that has been reported to increase HBV replication and gene expression, was under control of the JNK pathway. Notably, JNK activation increased FXR protein levels, not mRNA levels. Conclusion: Sorafenib suppressed HBV gene expression via inhibiting the JNK pathway, which regulates FXR activity.

show abstract

“…The HCC tissue obtains nutrients and oxygen from blood vessels by the process of angiogenesis (3,4). Vascular endothelial cells proliferate by activating the mitogen-activated protein (MAP) kinase pathway, which acts downstream of the vascular endothelial cell growth factor (VEGF) receptor (5). Sorafenib, a multikinase inhibitor of VEGF, inhibits the MAP kinase pathway and is used to treat HCC (6,7).…”

Section: Introductionmentioning

confidence: 99%